Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.42 |
| ▸ | CNR2 | P34972 | 5/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | CFD | P00746 | 1/20 | 0.39 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5451427 | 0.94 | PDE10A (0.48) | GAAACHEPDE10ACNR2SIGMAR1 | |
| SCHEMBL14412039 | 0.93 | GAA (0.42) | GAAACHEPDE10ACNR2SIGMAR1 | |
| SCHEMBL5442816 | 0.92 | CNR2 (0.43) | GAAACHEPDE10ACNR2SIGMAR1 | |
| SCHEMBL5454500 | 0.91 | CNR2 (0.48) | PDE10ACNR2LMNACHRM3 | |
| SCHEMBL5453707 | 0.89 | PDE10A (0.46) | PDE10ACNR2LMNACHRM3CXCR4 | |
| SCHEMBL5453582 | 0.89 | PDE10A (0.43) | GAAACHEPDE10ACNR2SIGMAR1 | |
| SCHEMBL14412046 | 0.85 | SIGMAR1 (0.40) | GAAACHEPDE10ACNR2SIGMAR1 | |
| SCHEMBL5448906 | 0.85 | CNR2 (0.48) | PDE10ACNR2LMNACHRM3 | |
| SCHEMBL5454578 | 0.85 | PDE10A (0.51) | PDE10ACNR2SIGMAR1ALDH1A1CHRM3 | |
| SCHEMBL5454797 | 0.85 | CNR2 (0.50) | GAAPDE10ACNR2ALDH1A1ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
| WO-2007079239-A2 | BICYCLIC NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | GIPR, GHSR, GHRHR | GAA 1095/4885ACHE 3240/4885PDE10A 514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.